Jubilant Pharmova Spokane Facility Gets US FDA VAI Status

1 Minute Read Listen to Article

Sep 11, 2026 22:28

Jubilant Pharmova's Spokane facility received a 'Voluntary Action Indicated' (VAI) status from the US FDA, meaning no regulatory action is planned.

Jubilant Pharmova Spokane Facility Gets US FDA VAI Status

Photograph: Kind courtesy jorono/Pixabay.com

Key Points

Jubilant Pharmova's Spokane facility received a 'Voluntary Action Indicated' (VAI) status from the US FDA.
The VAI classification indicates the US FDA does not intend to take administrative or regulatory action.
The company is expected to voluntarily resolve any objectionable conditions found during the inspection.
The inspection of the Spokane facility was conducted from June 8-17, 2026.

New Delhi, Sep 11 (PTI) Jubilant Pharmova Ltd on Friday said the US health regulator has classified the contract manufacturing (CMO) facility of its step-down subsidiary, Jubilant HollisterStier LLC, in Spokane, Washington, as 'Voluntary Action Indicated' (VAI).

The US Food and Drug Administration (US FDA) concluded its review of the Establishment Inspection Report (EIR) for the inspection conducted at the Spokane facility from June 8, 2026, to June 17, 2026, the company said in a regulatory filing.

A VAI classification indicates that while objectionable conditions or practices were found during the inspection, the agency does not intend to recommend any administrative or regulatory action as the company is expected to voluntarily resolve them.

Jubilant HollisterStier LLC is a subsidiary of Jubilant Pharma Holding Inc., which is a unit of Singapore-based Jubilant Pharma Limited-a wholly-owned subsidiary of Jubilant Pharmova Ltd.

Source: PTI By Rediff Money Desk, New Delhi

DISCLAIMER - This article is from a syndicated feed. The original source is responsible for accuracy, views & content ownership. Views expressed may not reflect those of rediff.com India Limited.